Description: | BMS-986260, an immuno-oncology agent, is a potent, selective, and orally active TGF?R1 inhibitor (IC50=1.6 nM). BMS-986260 displays exquisite selectivity for TGF?R1 over its isozyme TGF?R2, as well as in a panel of more than 200 kinases examined. BMS-986260 inhibits TGF? mediated nuclear translocation of pSMAD2/3 in MINK and NHLF cells lines with an IC50 of 350 nM and 190 nM, respectively[1]. |